A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

NCT00451958 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

386

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Degarelix 80 mg / Degarelix 80 mg
DRUG: Degarelix 160 mg / Degarelix 160 mg
DRUG: Leuprolide 7.5 mg / Degarelix 80 mg
DRUG: Leuprolide 7.5 mg / Degarelix 160 mg

Sponsor

Ferring Pharmaceuticals